Theralase(R) Granted Canadian Cancer Vaccine Patent - Seite 2

Roger DuMoulin-White, President and Chief Executive Officer of Theralase stated, "The possibilities and opportunities of our PDC technology continue to grow at a rapid pace. The Company plans to become properly financed this year through various equity and debt instruments to allow the Company the opportunity to commence new clinical studies focused on the destruction of both solid-core and liquid cancers. I am excited about the opportunities available to the Company, as a result of these new patents, as it significantly increases the opportunity for our PDC technology to treat patients inflicted with a wide range of cancers."

About Leukemia:

Leukemia is a cancer that starts in the stem cells of blood. As the stem cells of the blood develop, they become blast cells (blasts), which are immature blood cells. In leukemia, there is an overproduction of blast cells. These blast cells develop abnormally and don't develop into mature blood cells. Over time, the blast cells crowd out normal blood cells so that they can't do their jobs.

Leukemia is the 11^th most common cancer in the United States. As of 2019, more than 470,000 Americans have a history of leukemia. It was estimated that about 60,000 people would be diagnosed with leukemia in 2022. The five-year relative survival rate of leukemia is 65.7%.

About Lymphoma:

Lymphoma is a type of cancer that occurs due to the malignant transformation of the lymphocytes (infection fighting cells of the immune system). The most common category of lymphoma, Non-Hodgkin Lymphoma ("NHL") is the 7^th most common cancer in the United States. In 2024, the American Cancer Society's estimates 80,620 people (44,590 males and 36,030 females) will be diagnosed with NHL. The five-year relative survival rate of lymphoma is 72%.

About Myeloma:

Myeloma, also known as multiple myeloma, is a type of blood cancer that develops from plasma cells in the bone marrow. Myeloma is the 14^th most common type of cancer. In 2023, an estimated 35,730 adults in the United States will be diagnosed with multiple myeloma. The overall 5-year survival rate for people with multiple myeloma in the United States is 55%.

About Ruvidar^TM:

Ruvidar^TM is a peer-reviewed, patented PDC currently under investigation in a Phase II registration clinical study for bladder cancer.

About Theralase Technologies Inc.:

Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.